Document Detail

Comparative Effectiveness on Survival of Zoledronic Acid versus Pamidronate in Multiple Myeloma.
MedLine Citation:
PMID:  24844358     Owner:  NLM     Status:  Publisher    
ABSTRACT Zoledronic acid and pamidronate are the two bisphosphonates approved to reduce multiple myeloma skeletal complications in the United States. Little prior evidence exists comparing survival outcomes between the two. We evaluated the incidence of skeletal related events and overall survival in myeloma patients treated with zoledronic acid versus pamidronate using a cohort of 1,018 United States Veterans. At median follow-up of 26.9 months, patients receiving zoledronic acid had a 22% reduction in risk of death compared to pamidronate (hazard ratio (HR) 0.78; 95% CI, 0.67-0.92). The benefit persisted after controlling for potential confounders. Adjusted Cox modeling with inverse probability weighting and propensity score matching supported these findings. Zoledronic acid was also associated with a 25% decrease in skeletal-related events. Zoledronic acid is associated with increased overall survival and decreased skeletal related events compared to pamidronate in patients with multiple myeloma and should become the preferred bisphosphonate.
Km Sanfilippo; B Gage; S Luo; K Weilbaecher; M Tomasson; R Vij; G Colditz; K Carson
Related Documents :
15315398 - Supplementation with grape seed polyphenols results in increased urinary excretion of 3...
15563208 - Antioxidant activity and constituents of propolis collected in various areas of korea.
18680298 - Total phenolics, phenolic acids, isoflavones, and anthocyanins and antioxidant properti...
20614788 - Cd uptake in rice cultivars treated with organic acids and edta.
15834128 - Compartmental modeling to quantify alpha-linolenic acid conversion after longer term in...
12623078 - Geographic variations, cloning, and functional analyses of the venom acidic phospholipa...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-5-21
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  -     ISSN:  1029-2403     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  2014 May 
Date Detail:
Created Date:  2014-5-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  -    
Other Details:
Languages:  ENG     Pagination:  1-22     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chromosome 8q24.1/c-MYC Abnormality: A Marker for High-Risk Myeloma.
Next Document:  Repressed BMP-signalling reactivates NKL homeobox gene MSX1 in a T-ALL subset.